Short Interest in Medicus Pharma Ltd (NASDAQ:MDCX) Rises By 57.1%

Medicus Pharma Ltd (NASDAQ:MDCX) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 775,343 shares, a growth of 57.1% from the November 30th total of 493,429 shares. Based on an average daily volume of 422,422 shares, the short-interest ratio is currently 1.8 days. Currently, 4.0% of the shares of the stock are short sold. Currently, 4.0% of the shares of the stock are short sold. Based on an average daily volume of 422,422 shares, the short-interest ratio is currently 1.8 days.

Institutional Investors Weigh In On Medicus Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of Medicus Pharma in the 2nd quarter worth about $41,000. Osaic Holdings Inc. raised its position in Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares during the period. Brave Asset Management Inc. bought a new stake in Medicus Pharma in the third quarter worth about $46,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Medicus Pharma during the third quarter valued at approximately $59,000. Finally, May Hill Capital LLC purchased a new position in shares of Medicus Pharma during the second quarter valued at approximately $107,000.

Analyst Upgrades and Downgrades

MDCX has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Medicus Pharma in a research note on Monday, December 15th. Finally, Zacks Research raised Medicus Pharma to a “hold” rating in a research note on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Medicus Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.50.

Medicus Pharma Price Performance

NASDAQ:MDCX opened at $1.57 on Monday. The firm has a market capitalization of $34.48 million and a price-to-earnings ratio of -0.73. Medicus Pharma has a 1 year low of $1.49 and a 1 year high of $8.94. The business has a 50 day simple moving average of $2.09 and a 200-day simple moving average of $2.37.

Medicus Pharma (NASDAQ:MDCX) last released its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.27). As a group, analysts expect that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.